Richard Shell
Affiliations: | Nationwide Children's Hospital, Columbus, Ohio, United States |
Google:
"Richard Shell"Parents
Sign in to add mentor| Karen S McCoy | fellowship/program director | 1996-1999 | Nationwide Children's Hospital |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Al-Zaidy SA, Kolb SJ, Lowes L, et al. (2019) AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. Journal of Neuromuscular Diseases |
| Lowes LP, Alfano LN, Arnold WD, et al. (2019) Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. Pediatric Neurology |
| Shell R, Day J, Chiriboga C, et al. (2019) S61 Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): preliminary pulmonary and ventilatory findings from the phase 3 study (STR1VE) Thorax. 74 |
| Waldrop M, Lowes L, Toops J, et al. (2019) P.365Clinical outcomes in patients with spinal muscular atrophy type 1, 2 or 3 after 1 year of nusinersen therapy Neuromuscular Disorders. 29 |
| Mendell J, Shell R, Lehman K, et al. (2019) P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial Neuromuscular Disorders. 29 |
| Mendell JR, Shell R, Lehman KJ, et al. (2019) Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial Journal of the Neurological Sciences. 405: 271 |
| Al-Zaidy S, Pickard AS, Kotha K, et al. (2018) Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatric Pulmonology |
| Sheehan DW, Birnkrant DJ, Benditt JO, et al. (2018) Respiratory Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. 142: S62-S71 |
| Bartlett A, Kolb SJ, Kingsley A, et al. (2018) Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA! Contemporary Clinical Trials Communications. 11: 113-119 |
| Al-Zaidy S, Pickard A, Kotha K, et al. (2018) PSY16 - HEALTH OUTCOME IMPROVEMENTS IN SPINAL MUSCULAR ATROPHY TYPE 1 PATIENTS WITH AVXS-101 GENE REPLACEMENT THERAPY Value in Health. 21: S438 |